SANUWAVE Health, Inc.SNWVEarnings & Financial Report
SANUWAVE Health, Inc. is a medical technology company specializing in non-invasive regenerative care solutions. It develops and commercializes shock wave therapy systems for treating chronic wounds, diabetic foot ulcers, and orthopedic conditions, serving healthcare providers and patients across North America, Europe, and key Asia-Pacific markets.
SNWV Q4 FY2025 Key Financial Metrics
Revenue
$13.4M
Gross Profit
$10.0M
Operating Profit
$2.0M
Net Profit
$7.7M
Gross Margin
74.7%
Operating Margin
15.0%
Net Margin
57.4%
YoY Growth
30.3%
EPS
$0.78
SANUWAVE Health, Inc. Q4 FY2025 Financial Summary
SANUWAVE Health, Inc. reported revenue of $13.4M (up 30.3% YoY) for Q4 FY2025, with a net profit of $7.7M (up 157.8% YoY) (57.4% margin). Cost of goods sold was $3.4M, operating expenses totaled $8.0M.
Key Financial Metrics
| Total Revenue | $13.4M |
|---|---|
| Net Profit | $7.7M |
| Gross Margin | 74.7% |
| Operating Margin | 15.0% |
| Report Period | Q4 FY2025 |
SANUWAVE Health, Inc. Annual Revenue by Year
SANUWAVE Health, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $44.3M).
SANUWAVE Health, Inc. Quarterly Revenue & Net Profit History
SANUWAVE Health, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $13.4M | +30.3% | $7.7M | 57.4% |
| Q3 FY2025 | $11.4M | +22.9% | $9.7M | 84.8% |
| Q2 FY2025 | $10.1M | +43.4% | $551.0K | 5.4% |
| Q1 FY2025 | $9.3M | +63.5% | $-6.1M | -65.8% |
| Q4 FY2024 | $10.3M | +57.4% | $-13.3M | -129.5% |
| Q3 FY2024 | $9.3M | +92.7% | $-21.2M | -227.8% |
| Q2 FY2024 | $7.1M | +60.4% | $6.2M | 87.4% |
| Q1 FY2024 | $5.7M | +62.8% | $-4.8M | -84.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.7M | $7.1M | $9.3M | $10.3M | $9.3M | $10.1M | $11.4M | $13.4M |
| YoY Growth | 62.8% | 60.4% | 92.7% | 57.4% | 63.5% | 43.4% | 22.9% | 30.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $23.3M | $21.0M | $21.8M | $30.1M | $30.9M | $33.0M | $35.6M | $37.3M |
| Liabilities | $70.9M | $60.6M | $82.1M | $45.9M | $51.7M | $51.8M | $43.2M | $35.7M |
| Equity | $-47.6M | $-39.6M | $-60.3M | $-15.8M | $-20.8M | $-18.8M | $-7.6M | $1.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $1.1M | $-668000 | $1.3M | $741000 | $-1.5M | $993000 | $1.1M | $3.3M |